CA2517155A1 - Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof - Google Patents

Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof Download PDF

Info

Publication number
CA2517155A1
CA2517155A1 CA002517155A CA2517155A CA2517155A1 CA 2517155 A1 CA2517155 A1 CA 2517155A1 CA 002517155 A CA002517155 A CA 002517155A CA 2517155 A CA2517155 A CA 2517155A CA 2517155 A1 CA2517155 A1 CA 2517155A1
Authority
CA
Canada
Prior art keywords
trifluoro
sulfonamide
thiophene
hydroxymethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002517155A
Other languages
English (en)
French (fr)
Inventor
Anthony Frank Kreft
Lynn Resnick
Scott Christian Mayer
George Diamantidis
Derek Cecil Cole
Tingzhong Wang
Rocco John Galante
Molly Hoke
Boyd Lynn Harrison
Minsheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth
Anthony Frank Kreft
Lynn Resnick
Scott Christian Mayer
George Diamantidis
Derek Cecil Cole
Tingzhong Wang
Rocco John Galante
Molly Hoke
Boyd Lynn Harrison
Minsheng Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth, Anthony Frank Kreft, Lynn Resnick, Scott Christian Mayer, George Diamantidis, Derek Cecil Cole, Tingzhong Wang, Rocco John Galante, Molly Hoke, Boyd Lynn Harrison, Minsheng Zhang filed Critical Wyeth
Publication of CA2517155A1 publication Critical patent/CA2517155A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
CA002517155A 2003-03-31 2004-03-26 Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof Abandoned CA2517155A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31
US60/459,228 2003-03-31
PCT/US2004/009268 WO2004092155A1 (en) 2003-03-31 2004-03-26 Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Publications (1)

Publication Number Publication Date
CA2517155A1 true CA2517155A1 (en) 2004-10-28

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002517155A Abandoned CA2517155A1 (en) 2003-03-31 2004-03-26 Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Country Status (22)

Country Link
US (3) US7300951B2 (US07858658-20101228-C00033.png)
EP (1) EP1608638A1 (US07858658-20101228-C00033.png)
JP (1) JP2006522126A (US07858658-20101228-C00033.png)
KR (1) KR20060002908A (US07858658-20101228-C00033.png)
CN (2) CN1780829B (US07858658-20101228-C00033.png)
AR (1) AR043940A1 (US07858658-20101228-C00033.png)
AU (1) AU2004230844B2 (US07858658-20101228-C00033.png)
BR (1) BRPI0408962A (US07858658-20101228-C00033.png)
CA (1) CA2517155A1 (US07858658-20101228-C00033.png)
CL (1) CL2004000647A1 (US07858658-20101228-C00033.png)
CO (1) CO5640049A2 (US07858658-20101228-C00033.png)
CR (1) CR7951A (US07858658-20101228-C00033.png)
EC (1) ECSP056128A (US07858658-20101228-C00033.png)
MX (1) MXPA05010368A (US07858658-20101228-C00033.png)
NO (1) NO20054263L (US07858658-20101228-C00033.png)
NZ (1) NZ542468A (US07858658-20101228-C00033.png)
RU (1) RU2342374C2 (US07858658-20101228-C00033.png)
SG (1) SG167669A1 (US07858658-20101228-C00033.png)
TW (1) TWI336698B (US07858658-20101228-C00033.png)
UA (1) UA82093C2 (US07858658-20101228-C00033.png)
WO (1) WO2004092155A1 (US07858658-20101228-C00033.png)
ZA (1) ZA200507896B (US07858658-20101228-C00033.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156268A0 (en) * 2000-12-13 2004-01-04 Wyeth Corp Heterocyclic sulfonamide inhibitors of beta amyloid production
MXPA04005927A (es) * 2001-12-20 2004-11-01 Squibb Bristol Myers Co Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo.
NZ536665A (en) * 2002-06-11 2006-11-30 Wyeth Corp Use of substituted phenylsulfonamide as inhibitors of beta amyloid production
RU2342374C2 (ru) * 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
DE602005016775D1 (de) * 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
US7838550B2 (en) * 2006-02-17 2010-11-23 Wyeth Llc Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
AU2007217965A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
MX2008013539A (es) 2006-04-21 2008-10-29 Wyeth Corp Produccion de intermediarios de amino alcohol quiralmente puros, derivados de los mismos, y usos de los mismos.
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
PE20090810A1 (es) * 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica
PA8789701A1 (es) * 2007-07-16 2009-04-23 Wyeth Corp Inhibidores de producción de beta amiloide
AR067534A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
AR070120A1 (es) * 2008-01-11 2010-03-17 Wyeth Corp Derivados de aril sulfonamida que contienen o-sulfato y o-fosfato, utiles como inhibidores de beta-amiloide, proceso de preparacion de los mismos y composiciones farmaceuticas que los contienen.
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
EP2334620B1 (en) 2008-09-05 2018-09-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
US9617239B2 (en) 2010-03-10 2017-04-11 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
KR920019763A (ko) 1991-04-26 1992-11-19 모리다 가즈라 아졸 화합물, 그의 제조방법 및 용도
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) * 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
IL110525A0 (en) 1993-08-09 1994-11-11 Lilly Co Eli Identification and use of protease inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
ES2293651T3 (es) * 1995-11-28 2008-03-16 Cephalon, Inc. Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
EP0939629A4 (en) 1996-07-22 2002-07-17 Monsanto Co THIOL-SULFONAMIDES AS METALLOPROTEINAS INHIBITORS
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
NZ335157A (en) 1996-11-22 2001-01-26 Elan Pharm Inc N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
DE19650196A1 (de) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
AU773273B2 (en) 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
CA2387493A1 (en) 1999-10-08 2001-04-19 Lorin Andrew Thompson Amino lactam sulfonamides as inhibitors of a.beta. protein production
EP1268412B8 (en) 2000-03-20 2007-02-21 MERCK SHARP & DOHME LTD. Sulphonamido-substituted bridged bicycloalkyl derivatives
IL156268A0 (en) * 2000-12-13 2004-01-04 Wyeth Corp Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JP4250529B2 (ja) 2001-12-11 2009-04-08 ワイス キラル的に純粋なβ−アミノアルコールの合成方法
CA2470111A1 (en) 2001-12-11 2003-06-19 Wyeth Production of chirally pure .alpha.-amino acids and n-sulfonyl .alpha.-amino acids
NZ536665A (en) * 2002-06-11 2006-11-30 Wyeth Corp Use of substituted phenylsulfonamide as inhibitors of beta amyloid production
RU2342374C2 (ru) * 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
US7838550B2 (en) * 2006-02-17 2010-11-23 Wyeth Llc Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
AU2007217965A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
MX2008013539A (es) * 2006-04-21 2008-10-29 Wyeth Corp Produccion de intermediarios de amino alcohol quiralmente puros, derivados de los mismos, y usos de los mismos.
AR067534A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
PA8789701A1 (es) * 2007-07-16 2009-04-23 Wyeth Corp Inhibidores de producción de beta amiloide
PE20090810A1 (es) * 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica

Also Published As

Publication number Publication date
CN101274926A (zh) 2008-10-01
ECSP056128A (es) 2006-03-01
US20090227667A1 (en) 2009-09-10
SG167669A1 (en) 2011-01-28
JP2006522126A (ja) 2006-09-28
UA82093C2 (uk) 2008-03-11
MXPA05010368A (es) 2005-11-17
US7300951B2 (en) 2007-11-27
RU2342374C2 (ru) 2008-12-27
TWI336698B (en) 2011-02-01
US7547725B2 (en) 2009-06-16
CN1780829A (zh) 2006-05-31
ZA200507896B (en) 2007-03-28
AU2004230844A1 (en) 2004-10-28
EP1608638A1 (en) 2005-12-28
NO20054263D0 (no) 2005-09-15
TW200504047A (en) 2005-02-01
CN1780829B (zh) 2010-12-29
CL2004000647A1 (es) 2005-02-04
NZ542468A (en) 2009-01-31
BRPI0408962A (pt) 2006-04-04
CO5640049A2 (es) 2006-05-31
WO2004092155A1 (en) 2004-10-28
AR043940A1 (es) 2005-08-17
KR20060002908A (ko) 2006-01-09
AU2004230844B2 (en) 2010-12-09
US20070254929A1 (en) 2007-11-01
RU2005133434A (ru) 2006-07-10
CR7951A (es) 2008-10-29
US7858658B2 (en) 2010-12-28
NO20054263L (no) 2005-12-14
US20040198778A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
CA2517155A1 (en) Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
CA2436526C (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
AU2006272837B2 (en) N-(arylamino)-sulfonamide inhibitors of MEK
AU2002245123A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
JP2007517905A (ja) アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤
US20090023801A1 (en) Inhibitors of beta amyloid production

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued